Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 4, Pages djw249
Publisher
Oxford University Press (OUP)
Online
2016-10-13
DOI
10.1093/jnci/djw249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
- (2016) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816
- (2016) Oliver W. Press et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses
- (2015) C. J. Saret et al. BLOOD
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
- (2015) Catherine S. Diefenbach et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma
- (2015) Hugo J.A. Adams et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
- (2015) Karolin Behringer et al. LANCET
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe
- (2014) Paul Hanly et al. INTERNATIONAL JOURNAL OF CANCER
- Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031
- (2014) Debra L. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
- (2014) John M.M. Raemaekers et al. JOURNAL OF CLINICAL ONCOLOGY
- The Impact of Protocol Assignment for Older Adolescents with Hodgkin Lymphoma
- (2014) Richard S. Pieters et al. Frontiers in Oncology
- An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma
- (2013) A. E. Hay et al. ANNALS OF ONCOLOGY
- Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival
- (2013) G. Venkataraman et al. BLOOD
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
- (2013) J. A. Kanakry et al. BLOOD
- Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma
- (2013) J. Ouyang et al. BLOOD
- MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma
- (2013) Beatriz Sánchez-Espiridión et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma
- (2013) P. R. Marri et al. CLINICAL CANCER RESEARCH
- EBV-Related Lymphomas: New Approaches to Treatment
- (2013) Jennifer A. Kanakry et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
- (2013) Emmanuel Itti et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)
- (2013) Lena Specht et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials
- (2013) Michael Zach Koontz et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
- (2013) Rajendra Gharbaran et al. Journal of Hematology & Oncology
- Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
- (2012) Maike Sauer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
- (2012) K. L. Tan et al. BLOOD
- Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
- (2012) C. Steidl et al. BLOOD
- Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
- (2012) K. Jones et al. CLINICAL CANCER RESEARCH
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
- International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era
- (2012) Alden A. Moccia et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
- (2012) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
- (2012) Paul Greaves et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
- (2012) Leo I. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group
- (2012) Cameron K. Tebbi et al. PEDIATRIC BLOOD & CANCER
- Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma
- (2011) S. Saarinen et al. BLOOD
- Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
- (2011) P. Kamper et al. BLOOD
- Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
- (2011) Floris H. P. van Velden et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Macrophages predict treatment outcome in Hodgkin's lymphoma
- (2011) C. Steidl et al. HAEMATOLOGICA
- Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
- (2011) Peter Borchmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Tumor Size and Tracer Uptake Heterogeneity in 18F-FDG PET and CT Non-Small Cell Lung Cancer Tumor Delineation
- (2011) M. Hatt et al. JOURNAL OF NUCLEAR MEDICINE
- Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
- (2011) Timothy Best et al. NATURE MEDICINE
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
- (2011) Ralph M. Meyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma
- (2011) D. C. Hodgson Hematology-American Society of Hematology Education Program
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
- (2010) S. M. Castellino et al. BLOOD
- Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses
- (2010) Andrea Gallamini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy
- (2010) George P. Canellos et al. JOURNAL OF CLINICAL ONCOLOGY
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
- (2010) Hans Theodor Eich et al. JOURNAL OF CLINICAL ONCOLOGY
- Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study
- (2010) Christine Mauz-Körholz et al. JOURNAL OF CLINICAL ONCOLOGY
- Reproducibility of 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements
- (2010) M. Hatt et al. JOURNAL OF NUCLEAR MEDICINE
- Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988–2005: an analysis of 21 734 cases
- (2010) Faiha Bazzeh et al. LEUKEMIA & LYMPHOMA
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
- (2009) C. L. Schwartz et al. BLOOD
- Malignant mesothelioma after radiation treatment for Hodgkin lymphoma
- (2009) M. L. De Bruin et al. BLOOD
- Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients
- (2009) Arjan Diepstra et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes
- (2009) Marie L. De Bruin et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma
- (2009) Marie L. De Bruin et al. JNCI-Journal of the National Cancer Institute
- Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
- (2008) D. Buglio et al. BLOOD
- Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma
- (2008) Roger Rautert et al. LEUKEMIA & LYMPHOMA
- Treatment of Hodgkin lymphoma: the past, present and future
- (2008) Andrew M Evens et al. Nature clinical practice. Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started